Please login to the form below
PRIME status
This page shows the latest PRIME status news and features for those working in and with pharma, biotech and healthcare.
First-in-class hepatitis B/D drug raises cure hope
It has been given a breakthrough designation by the FDA, Priority Medicines (PRIME) status by the EMA and has been awarded a Promising Innovative Medicine (PIM) designation from the MHRA in
Latest news
-
Janssen’s CAR-T gains PRIME status in Europe
The EMA’s PRIME status offers enhanced interaction and early dialogue to help companies accelerate their development plans and speed up evaluation for cutting-edge therapies in areas of high unmet ... The PRIME status could help it close the gap on its
-
US, EU regulators back rapid reviews of AZ’s RSV med
In Europe, MEDI8897 has been given PRIME status by the EMA, while the long-acting anti-RSV antibody has picked up a breakthrough designation from the FDA in the US. ... The FDA had already given the drug fast-track status, cutting its review time down to
-
Roche gains EU PRIME status for Spinraza rival
PRIME status takes it one step closer to fruition, as it will give Roche additional support from the EMA as the company prepares and files risdiplam for approval in Europe. ... Only one in five drugs submitted for PRIME end up being awarded the status.
-
FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease
In Europe, emapalumab has been granted orphan designation and PRIME (PRIority MEdicine) status by the EMA, and has been filed for approval with a verdict due in 2019.
-
Orchard plans IPO as gene therapy pipeline advances
beta thalassaemia – which has just bagged a Priority Medicines (PRIME) designation from the EMA. ... Orchard is playing catch-up in thalassaemia with Bluebird Bio, which is planning to file its LentiGlobin candidate in Europe before the end of this year
More from news
Approximately 1 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
The European Medicines Agency: PRIME’d for access?
Figure 1: Treatments with PRIME status by therapeutic area. Source: Analysis using EMA data after two years of PRIME. ... PRIME status is being touted as useful to help advance development of RG6042.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- 20 for 2020 – Five pharma companies to watch
- FDA approves Roche’s Actemra COVID-19 trial
- Moderna inks R&D agreements with Vertex and Chiesi
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
